## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates). Caution: declining volume (37% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($317.11)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co.**
- Source: MarketBeat | 20251227T124042 | Somewhat-Bullish | Relevance: 100%
- Meyer Handelman Co. recently reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 3.0%, selling 3,881 shares but still holding 124,913 shares valued at around $35.25 million, making Amgen its 28th largest holding. Amgen has demonstrated strong financial performance, beating quarterly earnings expectations and raising its quarterly dividend. The company also maintains a "Moderate Buy" consensus rating from analysts with a target price of $332.85.

**2. Carnegie Investment Counsel Has $30.27 Million Stake in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251227T102553 | Bullish | Relevance: 100%
- Carnegie Investment Counsel significantly increased its stake in Amgen Inc. (NASDAQ:AMGN) during Q3, now holding 107,260 shares valued at $30.27 million. This move comes as Amgen reported strong Q3 earnings, beating estimates with $5.64 EPS, and analysts maintain a "Moderate Buy" consensus with an average price target of $332.85. The company also raised its quarterly dividend to $2.52 per share, despite recent insider selling activity.

**3. Japan Gene Therapy Market is expected to reach US$ 904.94 Million by 2033 | Major Companies - Alnylam Pharmaceuticals, Inc., NOVARTIS AG, Sarepta Therapeutics, Inc., Krystal Biotech, Inc.**
- Source: openPR.com | 20251229T000919 | Bullish | Relevance: 85%
- The Japan Gene Therapy Market was valued at US$ 148.06 Million in 2024 and is projected to grow to US$ 904.94 Million by 2033, exhibiting a CAGR of 20.3%. This growth is fueled by increasing R&D, regulatory support, and advancements in personalized medicine. Key players in this market include Alnylam Pharmaceuticals, Inc., Novartis AG, Sarepta Therapeutics, Inc., and Krystal Biotech, Inc.

**4. Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?**
- Source: www.sharewise.com | 20251227T000846 | Somewhat-Bullish | Relevance: 78%
- The iShares Biotechnology ETF (IBB) is a prominent smart beta ETF in the Health Care sector, offering broad exposure to biotechnology and pharmaceutical companies. With over $8.68 billion in assets and a 0.44% expense ratio, it tracks the Nasdaq Biotechnology Index. While considered a high-risk choice due to its volatility, it has shown strong performance, gaining approximately 31.33% in the past year.

**5. Recombinant Therapeutic Antibodies And Proteins Market**
- Source: openPR.com | 20251229T053856 | Somewhat-Bullish | Relevance: 70%
- The Recombinant Therapeutic Antibodies And Proteins Market is projected for substantial growth from 2025 to 2032 due to rising demand, expanding applications, and technological advancements. Coherent Market Insights' report provides a comprehensive overview of market size, revenue trends, key growth factors, and competitive landscape. The study offers actionable insights for businesses to make informed decisions in this high-growth sector.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Forward P/E 15.0x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $177.5B |
| Beta | 0.45 |
| 52W Range | $257.05 - $346.38 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 15.0 |
| Current P/E | 15.5 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 0.0% (minimal 5-day change). Below STRENGTH zone by 4.0pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 53. Volume at 37% of 20MA suggests lack of conviction. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.00% (CS: 48) | Neutral |
| RSI_14 | 52.6 | Neutral |
| MACD Histogram | 0.11 | Bullish |
| vs SMA20 | 1.004x | Above |
| vs SMA50 | 1.024x | Above |
| vs SMA200 | 1.108x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $329.63
- **Stop Loss:** $317.11 (3.8% risk)
- **Target:** $354.67 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 110
- **Position Value:** $36,259.30
- **Portfolio %:** 36.26%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*